New oily agents for targeting chemoembolization for hepatocellular carcinoma

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Drug delivery systems

Background:

• Hepatocellular carcinoma (HCC) is a primary liver cancer with limited treatment options.
• Chemoembolization is a common treatment for HCC, often utilizing oily agents.
• Lipiodol has been the standard oily agent, but its efficacy and targeting can be improved.

Purpose of the Study:

• To evaluate novel non-iodinated oily agents and varying viscosities for chemoembolization in HCC.
• To assess the safety, distribution, retention, and imaging characteristics of these new agents.
• To compare the performance of these agents against traditional lipiodol.

Main Methods:

• Five oily preparations were tested in VX2 carcinoma-bearing rabbits.
• Preparations included non-iodinated oils with varying viscosities and modified lipiodol.
• Safety, histologic distribution, agent retention, and CT imaging were assessed post-injection.

Main Results:

• No hepatic parenchyma injury was observed with any preparation.
• Higher viscosity correlated with significantly greater agent retention at tumor sites.
• Non-iodinated agents provided better CT visualization of tumor staining compared to lipiodol.

Conclusions:

• Developed non-iodinated and highly viscous oily preparations are superior to lipiodol for HCC treatment.
• These novel agents offer improved tumor targeting and retention in chemoembolization.
• Further clinical studies are warranted to confirm these findings in human HCC patients.